SCHEMBL8016233

SCHEMBL8016233

[CH2]c1ccc(N(CCC)C(C)=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 3/20 0.40
TP53 P04637 2/20 0.40
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
NPC1 O15118 1/20 0.34
JAK2 O60674 1/20 0.34
RAB9A P51151 1/20 0.34
PAX8 Q06710 1/20 0.34
ACHE P22303 2/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
MEN1 O00255 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6698097 0.83 TP53 (0.44) MLYCDTP53ALDH1A1SMN1; SMN2RAB9A
SCHEMBL15215895 0.81 POLB (0.49) MLYCDTP53ALDH1A1ACHEMEN1
SCHEMBL2069635 0.81 TP53 (0.59) TP53ALDH1A1GLATSHRSMN1; SMN2
SCHEMBL8425367 0.79 PARP10 (0.43) MLYCDTP53ALDH1A1SMN1; SMN2EGFR
SCHEMBL5510305 0.78 TP53 (0.40) MLYCDTP53ALDH1A1GLATSHR
SCHEMBL22241398 0.77 MLYCD (0.41) MLYCDTP53ALDH1A1TSHRSMN1; SMN2
SCHEMBL22241317 0.76 MLYCD (0.38) MLYCDTP53ALDH1A1TSHRSMN1; SMN2
SCHEMBL8009661 0.74 TSPO (0.62) ALDH1A1GLASMN1; SMN2TRPM8NPC1
SCHEMBL9614627 0.73 HSD17B3 (0.44) MLYCDALDH1A1TSHRSMN1; SMN2NPC1
SCHEMBL22241327 0.73 MLYCD (0.38) MLYCDTP53ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed